Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells

Clinical Immunology

Volumn 152, Issue 1-2, 2014, Pages 115-126

  Cunnusamy, Khrishen ^a   Baughman, Ethan J ^a   Franco, Jorge ^a   Ortega, Sterling B ^a   Sinha, Sushmita ^b   Chaudhary, Parul ^a   Greenberg, Benjamin M ^a   Frohman, Elliot M ^a   Karandikar, Nitin J ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

CD8; IL 12; Multiple sclerosis; Regulatory; T cells

Indexed keywords

BETA1A INTERFERON; CD27 ANTIGEN; CD45RO ANTIGEN; FINGOLIMOD; GAMMA INTERFERON; GLATIRAMER; GRANZYME B; INTERLEUKIN 12; NATALIZUMAB; PERFORIN; RITUXIMAB;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LYMPHOCYTE DIFFERENTIATION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; UPREGULATION;

CD8; IL-12; MULTIPLE SCLEROSIS; REGULATORY; T CELLS;

ADULT; AGED; ANTIGENS, CD27; ANTIGENS, CD45; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; DISEASE PROGRESSION; FEMALE; GRANZYMES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PERFORIN; T-LYMPHOCYTES, REGULATORY; UP-REGULATION; YOUNG ADULT;

EID: 84897931965     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.03.005     Document Type: Article

References (47)

1. Kantarci O., Wingerchuk D. Epidemiology and natural history of multiple sclerosis: new insights. Curr. Opin. Neurol. 2006, 19:248-254.
2. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
3. Trapp B.D., Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu. Rev. Neurosci. 2008, 31:247-269.
4. Ontaneda D., Hyland M., Cohen J.A. Multiple sclerosis: new insights in pathogenesis and novel therapeutics. Annu. Rev. Med. 2012, 63:389-404.
5. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
6. Bhat R., Steinman L. Innate and adaptive autoimmunity directed to the central nervous system. Neuron 2009, 64:123-132.
7. McFarland H.F., Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 2007, 8:913-919.
8. Vignali D.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat. Rev. Immunol. 2008, 8:523-532.
9. Lowther D.E., Hafler D.A. Regulatory T cells in the central nervous system. Immunol. Rev. 2012, 248:156-169.
10. Venken K., Hellings N., Liblau R., Stinissen P. Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol. Med. 2010, 16:58-68.
11. Viglietta V., Baecher-Allan C., Weiner H.L., Hafler D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 2004, 199:971-979.
12. Venken K., Hellings N., Broekmans T., Hensen K., Rummens J.L., Stinissen P. Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J. Immunol. 2008, 180:6411-6420.
13. Seo S.K., Choi J.H., Kim Y.H., Kang W.J., Park H.Y., Suh J.H., et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat. Med. 2004, 10:1088-1094.
14. Wang R., Han G., Song L., Wang J., Chen G., Xu R., et al. CD8+ regulatory T cells are responsible for GAD-IgG gene-transferred tolerance induction in NOD mice. Immunology 2009, 126:123-131.
15. Davila E., Kang Y.M., Park Y.W., Sawai H., He X., Pryshchep S., et al. Cell-based immunotherapy with suppressor CD8+ T cells in rheumatoid arthritis. J. Immunol. 2005, 174:7292-7301.
16. Bisikirska B., Colgan J., Luban J., Bluestone J.A., Herold K.C. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J. Clin. Invest. 2005, 115:2904-2913.
17. Klimiuk P.A., Goronzy J.J., Weyand C.M. IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis. J. Immunol. 1999, 162:4293-4299.
18. Filaci G., Fenoglio D., Indiveri F. CD8(+) T regulatory/suppressor cells and their relationships with autoreactivity and autoimmunity. Autoimmunity 2011, 44:51-57.
19. Crawford M.P., Yan S.X., Ortega S.B., Mehta R.S., Hewitt R.E., Price D.A., et al. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 2004, 103:4222-4231.
20. Baughman E.J., Mendoza J.P., Ortega S.B., Ayers C.L., Greenberg B.M., Frohman E.M., et al. Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis. J. Autoimmun. 2011, 36:115-124.
21. Lee Y.H., Ishida Y., Rifa'i M., Shi Z., Isobe K., Suzuki H. Essential role of CD8+CD122+ regulatory T cells in the recovery from experimental autoimmune encephalomyelitis. J. Immunol. 2008, 180:825-832.
22. York N.R., Mendoza J.P., Ortega S.B., Benagh A., Tyler A.F., Firan M., et al. Immune regulatory CNS-reactive CD8+T cells in experimental autoimmune encephalomyelitis. J. Autoimmun. 2010, 35:33-44.
23. Barber A., Zhang T., Megli C.J., Wu J., Meehan K.R., Sentman C.L. Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma. Exp. Hematol. 2008, 36:1318-1328.
24. Langhans B., Ahrendt M., Nattermann J., Sauerbruch T., Spengler U. Comparative study of NK cell-mediated cytotoxicity using radioactive and flow cytometric cytotoxicity assays. J. Immunol. Methods 2005, 306:161-168.
25. Thiery J., Walch M., Jensen D.K., Martinvalet D., Lieberman J. Isolation of cytotoxic T cell and NK granules and purification of their effector proteins. Curr. Protoc. Cell Biol. 2010, 37:3.37.1-3.37.29.
26. Smith T.R., Kumar V. Revival of CD8+ Treg-mediated suppression. Trends Immunol. 2008, 29:337-342.
27. Konya C., Goronzy J.J., Weyand C.M. Treating autoimmune disease by targeting CD8(+) T suppressor cells. Expert. Opin. Biol. Ther. 2009, 9:951-965.
28. Chowdhury F.Z., Ramos H.J., Davis L.S., Forman J., Farrar J.D. IL-12 selectively programs effector pathways that are stably expressed in human CD8+ effector memory T cells in vivo. Blood 2011, 118:3890-3900.
29. McCarron M.J., Reen D.J. Neonatal CD8+ T-cell differentiation is dependent on interleukin-12. Hum. Immunol. 2010, 71:1172-1179.
30. Curtsinger J.M., Lins D.C., Mescher M.F. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J. Exp. Med. 2003, 197:1141-1151.
31. Babbe H., Roers A., Waisman A., Lassmann H., Goebels N., Hohlfeld R., et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 2000, 192:393-404.
32. Niland B., Banki K., Biddison W.E., Perl A. CD8+ T cell-mediated HLA-A*0201-restricted cytotoxicity to transaldolase peptide 168-176 in patients with multiple sclerosis. J. Immunol. 2005, 175:8365-8378.
33. Jurewicz A., Biddison W.E., Antel J.P. MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes. J. Immunol. 1998, 160:3056-3059.
34. -/- mice. Science 1992, 256:1210-1213.
35. Jiang H., Zhang S.I., Pernis B. Role of CD8+ T cells in murine experimental allergic encephalomyelitis. Science 1992, 256:1213-1215.
36. Ortega S.B., Kashi V.P., Tyler A.F., Cunnusamy K., Mendoza J.P., Karandikar N.J. The disease-ameliorating function of autoregulatory CD8 T cells is mediated by targeting of encephalitogenic CD4 T cells in experimental autoimmune encephalomyelitis. J. Immunol. 2013, 191:117-126.
37. Ratts R.B., Lovett-Racke A.E., Choy J., Northrop S.C., Hussain R.Z., Karandikar N.J., et al. CD28-CD57+ T cells predominate in CD8 responses to glatiramer acetate. J. Neuroimmunol. 2006, 178:117-129.
38. Antel J., Bania M., Noronha A., Neely S. Defective suppressor cell function mediated by T8+ cell lines from patients with progressive multiple sclerosis. J. Immunol. 1986, 137:3436-3439.
39. Balashov K.E., Khoury S.J., Hafler D.A., Weiner H.L. Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis. J. Clin. Invest. 1995, 95:2711-2719.
40. Correale J., Villa A. Isolation and characterization of CD8+ regulatory T cells in multiple sclerosis. J. Neuroimmunol. 2008, 195:121-134.
41. Correale J., Villa A. Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis. Ann. Neurol. 2010, 67:625-638.
42. Tennakoon D.K., Mehta R.S., Ortega S.B., Bhoj V., Racke M.K., Karandikar N.J. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J. Immunol. 2006, 176:7119-7129.
43. Durrenberger P.F., Webb L.V., Sim M.J., Nicholas R.S., Altmann D.M., Boyton R.J. Increased HLA-E expression in white matter lesions in multiple sclerosis. Immunology 2012, 137:317-325.
44. Pender M.P., Csurhes P.A., Pfluger C.M., Burrows S.R. CD8 T cell deficiency impairs control of Epstein-Barr virus and worsens with age in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2012, 83:353-354.
45. Wang Z., Hong J., Sun W., Xu G., Li N., Chen X., et al. Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. J. Clin. Invest. 2006, 116:2434-2441.
46. Tyler A.F., Mendoza J.P., Firan M., Karandikar N.J. CD8 T cells are required for glatiramer acetate therapy in autoimmune demyelinating disease. PLoS One 2013, 8:e66772.
47. Schneider A., Long S.A., Cerosaletti K., Ni C.T., Samuels P., Kita M., et al. In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive Tregs involves IL-6-mediated signaling. Sci. Transl. Med. 2013, 5:170ra15.